Product details
GHRP-2 (also known as Pralmorelin) is a synthetic hexapeptide (D-Ala-D-2-Nal-Ala-Trp-D-Phe-Lys-NH2) and a GHSR (ghrelin / growth-hormone secretagogue receptor) agonist within the broader GHRP family. GHRP-2 produces robust GH release and was historically approved as a diagnostic agent for evaluating GH-secretory capacity, particularly in Japan where it has been used clinically as Pralmorelin. Compared with Ipamorelin (the GH-selective member of the family), GHRP-2 has somewhat broader receptor activity that also drives cortisol and prolactin release at higher doses, the trade-off being slightly larger GH-release magnitudes at the cost of less-clean receptor selectivity.
Peptuno supplies GHRP-2 (Pralmorelin) as a lyophilized powder at ≥99.0% HPLC purity. The hexapeptide synthesis is straightforward, and the analytical packet covers peak-integration HPLC plus mass spec. Two standard fill sizes (5 mg and 10 mg) cover typical research workflows. For research workflows where clean GH-selectivity matters (avoiding cortisol-axis confounders), Ipamorelin is the more appropriate choice; GHRP-2 is preferred when maximum GH-release magnitude is the priority over receptor selectivity.
FAQ
- How does GHRP-2 differ from Ipamorelin in receptor selectivity?
- Both peptides are GHSR (ghrelin receptor) agonists, but their selectivity profiles diverge meaningfully. Ipamorelin is highly selective for GHSR over the receptors that regulate cortisol, prolactin, and ACTH release, making it the cleanest GH-selective member of the GHRP family. GHRP-2 has broader activity, producing larger absolute GH-release magnitudes but with measurable secondary effects on cortisol and prolactin axes at higher doses. For research workflows where clean GH-selectivity matters (avoiding cortisol-axis confounders in cellular or in vivo readouts), Ipamorelin is the more appropriate choice; GHRP-2 is preferred when maximum GH-release amplitude is the primary endpoint. Both pair well with CJC-1295 in dual-pathway protocols, though the canonical commercial blend is built around Ipamorelin.
- What's the regulatory history of GHRP-2 as Pralmorelin?
- GHRP-2 was approved in Japan in 2006 under the generic name Pralmorelin (brand: GHRP Kaken) as a diagnostic agent for evaluating growth-hormone-secretory capacity in suspected adult GH deficiency. The approval was based on the molecule's reliable GH-release response in subjects with intact pituitary function and the absence of response in subjects with GH deficiency. The diagnostic-use indication remains the only approved indication for GHRP-2 in any major jurisdiction; the molecule is widely used as a research tool for GHSR pathway studies but lacks therapeutic-use approval. Buyers in Japan can reference the local clinical-use documentation; buyers elsewhere should treat GHRP-2 as a research-use compound.
Certificate of Analysis (COA)
The per-lot COA for this product will appear here.